GMED Globus Medical Inc Class A

Globus Medical Showcases Latest Innovations at NASS 2019

Globus Medical Showcases Latest Innovations at NASS 2019

Technologies featured include Single Position Lateral Surgery driven by ExcelsiusGPS® Interbody Solutions

AUDUBON, Pa., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will highlight the company’s latest spinal implant and enabling technology innovations at the North American Spine Society (NASS) Annual Meeting held September 25-28, 2019 in Chicago, IL at booth #2218.

“We are proud to be a NASS sponsor and this year’s meeting is very exciting as we plan to unveil several new technologies poised for launch,” said Dave Demski, Chief Executive Officer. “With the addition of the ExcelsiusGPS® Interbody Solutions platform, we will demonstrate the integration of our best-in-class surgical planning, robotic navigation, and expandable interbody technologies designed to enhance operating room efficiency and improve clinical results in spine surgery.”

The company’s participation includes in-booth surgeon presentations on the next evolution of the ExcelsiusGPS® platform featuring Interbody Solutions. This new solution offers navigation with constant real-time feedback during dilation, disc preparation, and implant insertion to help achieve optimal implant placement for minimally invasive posterior and lateral lumbar interbody fusion procedures. The platform’s rigid robotic arm maximizes retractor stability and creates a strong and stable working channel. Using today’s most comprehensive, robotic-assisted spine surgery platform, surgeons will be able to navigate instruments and implants with the most advanced expandable interbody portfolio on the market.

The exhibit will also include live demonstrations of Globus Medical’s Single Position Lateral Surgery technique, which has been increasingly utilized by surgeons over the last few years. Single Position Lateral Surgery is a fully integrated procedural solution that combines robotic and navigation enabling technologies with advanced musculoskeletal implant systems to treat complex multi-level spine pathologies from a single lateral position. Procedures that traditionally required multi-staged surgery using anterior, lateral, and posterior patient positions to treat spinal levels including L5-S1 can now be performed while the patient remains in one lateral position.  This technique has the potential to provide tangible benefits for surgeons, hospitals, and patients in terms of time, accuracy, surgical efficiency, and reduced radiation exposure through a holistic surgical solution.

Additional new technologies will be exhibited including CREO® NXT Stabilization System, SI-LOK® Select Sacroiliac Joint Fixation, and the full line of HEDRON™ 3D Printed Spacers.

Globus welcomes NASS attendees to visit  for a complete list of event details and to register for the presentations featured below:

Wednesday, September 25th



The Next Evolution of Posterior MIS with ExcelsiusGPS® Interbody Solutions

10:00am -10:30am, Exhibit Hall Booth #2218

Sheeraz Qureshi, MD, MBA

Single Position Lateral Surgery with ExcelsiusGPS® and Expandable Technology

3:05 pm – 3:35 pm, Exhibit Hall Booth #2218

Vladimir Sinkov, MD

Thursday, September 26th

HEDRON™ 3D Printed Spacers: Engineered for Fusion

3:00 pm – 3:30 pm, Exhibit Hall Booth #2218

Frank La Marca, MD

NASS After Hours featuring ExcelsiusGPS®: A Comprehensive Solution for Spine Surgery

Presentation: 3:30 pm - 5:15 pm, Gold Theater, Exhibit Hall Booth #1310

BioSkills Lab: 5:00 pm – 8:00 pm, Orange Lab, Exhibit Hall Booth #1310

Hoon Choi, MD, MS

About Globus Medical, Inc.

, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at .

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns

Senior Vice President, Business Development and Investor Relations

Phone: (610) 930-1800

Email:

EN
19/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

 PRESS RELEASE

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Globus Medical Reports Fourth Quarter and Full Year 2025 Results AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for ...

 PRESS RELEASE

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Re...

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...

 PRESS RELEASE

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over ...

Globus Medical Inc: 1 director

A director at Globus Medical Inc sold 4,000 shares at 88.850USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

Globus Medical Reports Third Quarter 2025 Results

Globus Medical Reports Third Quarter 2025 Results AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share (“EP...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch